小柯机器人

大规模平行筛查鉴定出天然配对的人类TCRαβ库
2020-03-17 10:33

美国GigaMune公司David S. Johnson团队利用大规模平行筛查与挖掘,发现天然配对的人类TCRαβ库。这一研究成果于2020年3月16日在线发表在《自然—生物技术》杂志上。

研究人员提出了一种高通量方法,可从各种人类T细胞库中鉴定具有高功能亲和力的T细胞受体(TCR)。该方法使用大规模并行微流控技术从数百万个原代T细胞中生成天然配对的全长TCRαβ克隆文库,然后在Jurkat细胞中表达。TCRαβ–Jurkat文库可以使用主要的肽组织相容性复合物结合和细胞活化功能,对抗原反应性TCR进行重复筛选和淘选。研究人员从六位健康的人类供体中捕获了超过290万组自然配对的TCRαβ克隆型,并确定了罕见的(<0.001%频率)病毒-抗原反应性TCR。研究人员还从一名黑色素瘤患者中提取了一个浸润肿瘤的淋巴细胞样品,并鉴定了几种肿瘤特异性TCR,这些TCR在原代T细胞中表达后可导致肿瘤细胞被杀死。
 
据悉,经过工程改造以表达抗原特异性TCR的T细胞是用于病毒感染和癌症的有效疗法。然而,由于T细胞库的大小和复杂性以及使用原代T细胞的难度,临床候选TCR的有效鉴定变得复杂。
 
附:英文原文

Title: Massively parallel interrogation and mining of natively paired human TCRαβ repertoires

Author: Matthew J. Spindler, Ayla L. Nelson, Ellen K. Wagner, Natasha Oppermans, John S. Bridgeman, James M. Heather, Adam S. Adler, Michael A. Asensio, Robert C. Edgar, Yoong Wearn Lim, Everett H. Meyer, Robert E. Hawkins, Mark Cobbold, David S. Johnson

Issue&Volume: 2020-03-16

Abstract: T cells engineered to express antigen-specific T cell receptors (TCRs) are potent therapies for viral infections and cancer. However, efficient identification of clinical candidate TCRs is complicated by the size and complexity of T cell repertoires and the challenges of working with primary T cells. Here we present a high-throughput method to identify TCRs with high functional avidity from diverse human T cell repertoires. The approach used massively parallel microfluidics to generate libraries of natively paired, full-length TCRαβ clones, from millions of primary T cells, which were then expressed in Jurkat cells. The TCRαβ–Jurkat libraries enabled repeated screening and panning for antigen-reactive TCRs using peptide major histocompatibility complex binding and cellular activation. We captured more than 2.9 million natively paired TCRαβ clonotypes from six healthy human donors and identified rare (<0.001% frequency) viral-antigen-reactive TCRs. We also mined a tumor-infiltrating lymphocyte sample from a patient with melanoma and identified several tumor-specific TCRs, which, after expression in primary T cells, led to tumor cell killing.

DOI: 10.1038/s41587-020-0438-y

Source: https://www.nature.com/articles/s41587-020-0438-y

Nature Biotechnology:《自然—生物技术》,创刊于1996年。隶属于施普林格·自然出版集团,最新IF:68.164
官方网址:https://www.nature.com/nbt/
投稿链接:https://mts-nbt.nature.com/cgi-bin/main.plex


本期文章:《自然—生物技术》:Online/在线发表

分享到:

0